Big ideas
Bold leaders
Experts and bold leaders set to inspire at Longevity Summit Dublin
Meet the experts
More to be announced soon
The countdown to groundbreaking ideas starts now!
David Furman, PhD, is an Associate Professor at the Buck Institute for Research on Aging, where he also serves as Chief of the AI Platform and directs the Stanford 1,000 Immunomes Project at Stanford School of Medicine. He earned his doctorate in immunology (summa cum laude) from the University of Buenos Aires, Argentina, and further honed his expertise during postdoctoral work with Professor Mark M. Davis at Stanford. Dr. Furman’s research integrates artificial intelligence and systems immunology to decipher how the immune system influences aging and age-related chronic diseases. An innovator with over 20 patents, he has published extensively in top-tier journals, significantly advancing our understanding of immunosenescence and its impact on health.
Dobri Kiprov
Founder | Global Apheresis
Harvard trained immunologist and an internationally recognized pioneer in the field of apheresis and has more than 100 publications on the subject.
He has served two terms on the Board of Directors of American Society For Apheresis and is currently a member of the Board of Directors of the International Society of Apheresis and is a member of the editorial board of the Journal of Transfusion and Apheresis Science.
He has received multiple awards for his contributions to the field of apheresis and has served as Chairman of the Division of Immunotherapy at California Pacific Medical Center. He was the founder and President of the Bay Area Mobile Apheresis Program and Senior Vice President and Medical Director for Apheresis for Fresenius Medical Care, NA.
Recently, DK founded Global Apheresis and co-founded Lyfspan, a company devoted to the research of aging. He is also a senior visiting scientist at the Buck Institute for the Research of Aging.
Dr. Kiprov pioneered the use of Therapeutic Plasma Exchange (TPE) in ameliorating the effects of aging and is conducting a number of controlled and uncontrolled studies. The early results are already published.
Matt Kaeberlein
CEO | Optispan
Dr. Matt Kaeberlein is the Chief Executive Officer at Optispan, Inc., Affiliate Professor of Oral Health Sciences at the University of Washington, and Co-Director of the Dog Aging Project. Dr. Kaeberlein’s research interests are focused on understanding biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life for people and companion animals. He is a Fellow of the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the Gerontological Society of America (GSA). Dr. Kaeberlein has published more than 250 scientific papers in the field of aging biology and has received several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer’s Association, the Vincent Cristofalo Rising Star in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology. Dr. Kaeberlein is the founding Director of the University of Washington Healthy Aging and Longevity Research Institute, former Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging and the Biological Mechanisms of Healthy Aging Training Program at the University of Washington, and former CEO and Chair of the American Aging Association.
Robert Kelly
Cardiologist | Beacon Hospital
As a cardiologist and health transformation coach, I have over 20 years of experience in helping people improve their health and wellbeing through lifestyle medicine and behaviour design. I am the CEO and owner of RK Cardiology Health Improvement Coaching, a hybrid service that provides personalised and evidence-based coaching programs for individuals and groups who want to achieve optimal health.
I am a board member of the European Lifestyle Medicine Organization (ELMO), a non-profit organization that promotes the advancement and dissemination of lifestyle medicine in Europe and beyond. I collaborate with other health professionals, researchers, and policymakers to advocate for the integration of lifestyle medicine into health systems and education. My mission is to inspire and empower people to make positive changes in their lives and to create a healthier and happier society.
Brian Kennedy
Director, Centre for Healthy Longevity and Professor Departments of Biochemistry and Physiology at National University of Singapore
Internationally recognized for my research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of delaying, detecting, preventing and treating human aging and associated diseases.
From 2010 to 2016 I was the President and CEO of the Buck Institute for Research on Aging. Continuing my passion for longevity, I’m currently the Director of the Centre for Healthy Longevity at the Yong Loo Lin School of Medicine at National University Singapore. I also serve as a Distinguished Professor in Biochemistry and Physiology. The Centre seeks to demonstrate that ageing interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life. Other goals include world class preclinical research to better understand the biology of ageing and community-based approached to improve health quality with ageing in Singapore.
I have adjunct appointments at the Leonard Davis School of Gerontology at USC and the Department of Biochemistry at the University of Washington, where I served as a faculty member from 2001 to 2010.
In addition, I’m actively involved with a number of Biotechnology companies, serving in consulting and Board capacities, as is Scientific Director of Affirmative Health. Also serving as a Co-Editor-In-Chief at Aging Cell.
Finally, setting my footprint internationally I have been in China, where I was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014.
Martin O’Dea
CEO | Longevity Summit Dublin
Businessman, published author and current CEO of Longevity Events Limited, which hosts the annual Longevity Summit Dublin. I have lectured business strategy, mentored a number of organisations in strategic development and sit on a number of boards. My interests include accelerating technologies and their implications on healthcare and society at large.
Shannon Neilsen
Director | PureHealth
Shannon Neilsen is a driving force at Pure Health, where he champions innovative, holistic wellness solutions. At the heart of Pure Health’s mission to deliver evidence‐based, transformative healthcare, Shannon’s leadership reflects a steadfast commitment to integrating advanced health strategies with compassionate, patient‐centered care. His forward-thinking approach and dedication to community well-being have been instrumental in shaping initiatives that empower individuals to achieve optimal health. With a clear vision for the future of integrated wellness, Shannon’s work embodies the core principles of Pure Health—innovation, integrity, and a deep respect for the individual’s journey toward better health.
Judith Mueller
Biohacking Eve
Judith is a venture capital investor specialising in the longevity sector, a biohacker with over 15 years of experience, and a serial entrepreneur turned VC. She is building longevity clinics in the Middle East and co-founded the Longevity Clinic Builder Network. Judith also co-organises Longevity Week Berlin, bringing together thought leaders in healthspan optimisation. As an advisor to family offices and senior allocators, she focuses on non-biotech longevity investments and shares her personal insights on extending health and lifespan. Her mission is to contribute one gigayear of healthy lifespan to humanity by acting as an enabler, multiplier, and advocate for meaningful, systemic change.
She is also the founder of Biohacking Eve, a platform centred on women’s health optimisation, with the goal of empowering women through education and biohacking insights.
Yuta Lee
Founder & CEO | Accelerated Biosciences Corp
Yuta is the founder and CEO of Accelerated Bio, a regenerative medicine company based in Philadelphia commercializing the human Trophoblast Stem Cell (hTSC). hTSCs are the earliest pre-implantation, pre-placental cells that can be sourced ethically from an ectopic pregnancy. These naïve cells can scale to 85 population doublings with natural immune privilege, making them the most ideal starting cell source for allogeneic cell & gene therapies. The hTSC platform has been awarded 53 patents, providing freedom-to-operate for partners looking for a clear pathway to commercialization.
Yuta is passionate about accelerating cell & gene therapies to advance healthy longevity. Accelerated Bio’s pipeline includes Parkinson’s Disease, Type 1 Diabetes, as well as Cell Senescence for longevity.
Yuta has dual B.A. degrees in economics and legal studies from the University of California, Berkeley. Yuta earned his MBA in 2009 from China Europe International Business School (CEIBS) in Shanghai, China and graduated with the Outstanding Graduate of the Year Award.
Kennedy Schaal
Rejuve.Bio
Kennedy Schaal is a pioneering biotechnology executive transforming longevity research through cutting-edge AI and genomic technologies. As CEO of Rejuve.Bio, she leads innovative approaches in analyzing cross-organism aging pathways, leveraging neural-symbolic AI and machine learning to accelerate discoveries in age-related disease interventions.
With a background in evolutionary biology from UC Irvine, Kennedy specializes in genomic research, particularly her groundbreaking work with Drosophila Methuselah Flies. Her mission extends beyond scientific discovery—she’s committed to democratizing longevity research and developing targeted strategies to enhance human healthspan.
A thought leader at the intersection of biotechnology and artificial intelligence, Kennedy is reshaping our understanding of aging, one breakthrough at a time.
Morten Scheibye-Knudsen
University of Copenhagen
Morten Scheibye-Knudsen is an innovative researcher and thought leader dedicated to unraveling the molecular mechanisms of aging. His work delves into the intricacies of DNA repair, cellular resilience, and the biological pathways that underpin longevity, aiming to transform breakthrough scientific insights into practical strategies for extending healthspan. With an interdisciplinary approach that bridges rigorous academic research and entrepreneurial vision, Morten fosters collaborative efforts that drive forward our understanding of aging and its impact on quality of life. His commitment to advancing longevity science continues to inspire new directions in both research and application.
Michael Ringel
Chief Operating Officer at Life Biosciences
As the chief operating officer for Life Biosciences, Dr. Michael Ringel oversees corporate strategy, market intelligence, business development and investor and public relations. Prior to joining Life Bio, Michael was Managing Director and Senior Partner at Boston Consulting Group (BCG), where he worked for 25+ years, and served in various roles including as the global topic leader for Research and Product Development. He is on the Board of Hevolution Foundation US, the charitable organization focused on extending healthy aging for the benefit of all humanity, and the Board of American Federation for Aging Research, one of the oldest organizations supporting healthy aging through biomedical research. Dr. Ringel holds a B.A. in biology from Princeton University (summa cum laude), a Ph.D. in biology from Imperial College (NSF and Fulbright Fellowships), and a J.D. from Harvard Law School (cum laude).
Michael has a B.A. summa cum laude in biology from Princeton University, a Ph.D. in biology from Imperial College and a J.D. cum laude from Harvard Law School.
Liz Prrish
CEO & Founder, BioViva
Elizabeth Parrish is a pioneering gene therapy researcher and visionary leader transforming our understanding of aging. As CEO of BioViva, she drives innovative therapies targeting cellular aging and age-related diseases through advanced genetic interventions.
Her groundbreaking work focuses on developing transformative gene therapies that can potentially reverse aging processes, with BioViva’s CMV platform offering revolutionary approaches to extending human healthspan. Through initiatives like CodeKeeper™, Parrish is democratizing gene therapy research and accelerating scientific collaboration.
A bold advocate for addressing aging as a treatable medical condition, Elizabeth Parrish continues to challenge conventional medical paradigms, positioning BioViva at the forefront of longevity biotechnology.
Emma Teeling
Professor of Zoology | University College Dublin
Prof. Emma Teeling is a global leader in mammalian phylogenetics and comparative genomics, with a special focus on bat biology. As Professor of Zoology at University College Dublin and founder of the Laboratory of Molecular Evolution and Mammalian Phylogenetics, she has pioneered research on bat models for healthy ageing and disease tolerance. A Founding Director of Bat1K, her work—supported by prestigious awards like the ERC Starting Grant and Chevalier des Palmes Académiques—has transformed our understanding of mammalian adaptations and conservation.
Andrew Steele
Scientist, Author | Ageless: The new science of getting older without getting old
Andrew Steele is a visionary digital innovator and creative strategist based in the United Kingdom, whose work seamlessly bridges technology and design to craft transformative digital experiences. His portfolio reflects a deep commitment to harnessing cutting-edge technology for creative problem-solving and strategic innovation. Through his dynamic approach, Andrew inspires organizations to explore new frontiers in the digital landscape, embracing a future defined by endless possibilities. His thought leadership and practical expertise continue to influence the evolution of digital strategy, making him a sought-after speaker and consultant in his field.
Kenneth Scott
Co-Founder VivaSparkle Inc.
I am Kenneth, a seasoned biotech investor, rejuvenation biohacker, and syndicate lead for AngelList’s Human Longevity and Rejuvenation Syndicate. With a deep understanding of age-related infirmities and the therapeutic landscape, I challenge conventional notions of lifespan and healthspan, envisioning a future where rejuvenation transforms our understanding of longevity. I co-founded and manage VivaSparkle’s syndicate, investing in promising biotech companies, and spearhead the Riley Farm Development project promoting sustainable real estate and nature conservation. With a background in software development and a track record of innovative solutions, I bring expertise and passion to the field of rejuvenation. My relentless pursuit of groundbreaking solutions stems from a firm belief that rejuvenation holds the potential to redefine the limits of human longevity.